Literature DB >> 14507757

Ciprofloxacin susceptibility of Pseudomonas aeruginosa isolates from keratitis.

J A Lomholt1, M Kilian.   

Abstract

AIM: To examine the ciprofloxacin susceptibility of 106 Pseudomonas aeruginosa eye isolates from the United Kingdom, Denmark, India, the United States, and Australia, and to determine the molecular mechanisms of resistance.
METHODS: Ciprofloxacin susceptibility was tested by an agar dilution method; genomic DNA corresponding to the quinolone target genes gyrA and parC, and the regulatory genes mexR and nfxB controlling drug efflux systems, was amplified by PCR and sequenced; multilocus enzyme electrophoresis was performed to examine the genetic relation among resistant strains.
RESULTS: Three out of 90 keratitis isolates (3.3%), one from the United Kingdom and two from India, exhibited MIC values of 16 mg/l or 32 mg/l. The UK isolate had a mutation in gyrA (Thr83Ile), whereas the two Indian isolates showed mutations in both gyrA (Thr83Ile) and parC (Ser87Leu). The remaining isolates from keratitis, endophthalmitis, contact lens associated red eye (CLARE), and contact lens storage cases showed MIC values below 1 mg/l. Several allelic forms of gyrA and a single variation in the mexR gene product were detected in 10 ciprofloxacin susceptible strains.
CONCLUSIONS: The vast majority of eye isolates of P aeruginosa from European countries are fully susceptible to ciprofloxacin and the concentration of ciprofloxacin eye drops used for local treatment (3000 mg/l) exceeds MIC values for strains recorded as resistant. Mutations in more than one target gene were associated with higher MIC values.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14507757      PMCID: PMC1920786          DOI: 10.1136/bjo.87.10.1238

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  19 in total

1.  Study of the first contact management profile of cases of infectious keratitis: a hospital-based study.

Authors:  R B Vajpayee; T Dada; R Saxena; M Vajpayee; H R Taylor; P Venkatesh; N Sharma
Journal:  Cornea       Date:  2000-01       Impact factor: 2.651

Review 2.  Methods of multilocus enzyme electrophoresis for bacterial population genetics and systematics.

Authors:  R K Selander; D A Caugant; H Ochman; J M Musser; M N Gilmour; T S Whittam
Journal:  Appl Environ Microbiol       Date:  1986-05       Impact factor: 4.792

3.  Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  S Jalal; O Ciofu; N Hoiby; N Gotoh; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Emerging ciprofloxacin-resistant Pseudomonas aeruginosa.

Authors:  N A Chaudhry; H W Flynn; T G Murray; H Tabandeh; M O Mello; D Miller
Journal:  Am J Ophthalmol       Date:  1999-10       Impact factor: 5.258

5.  Epidemic population structure of Pseudomonas aeruginosa: evidence for a clone that is pathogenic to the eye and that has a distinct combination of virulence factors.

Authors:  J A Lomholt; K Poulsen; M Kilian
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

6.  Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.

Authors:  T Akasaka; M Tanaka; A Yamaguchi; K Sato
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

7.  Detection of ciprofloxacin-resistant Yersinia pestis by fluorogenic PCR using the LightCycler.

Authors:  L E Lindler; W Fan; N Jahan
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

8.  Prolonged persistence on the ocular surface of fortified gentamicin ointment as compared to fortified gentamicin eye drops.

Authors:  J A Lomholt; J K Møller; N Ehlers
Journal:  Acta Ophthalmol Scand       Date:  2000-02

9.  Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.

Authors:  Rookaya Mather; Lisa M Karenchak; Eric G Romanowski; Regis P Kowalski
Journal:  Am J Ophthalmol       Date:  2002-04       Impact factor: 5.258

10.  Limited diversity of the immunoglobulin A1 protease gene (iga) among Haemophilus influenzae serotype b strains.

Authors:  K Poulsen; J P Hjorth; M Kilian
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

View more
  6 in total

Review 1.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

2.  Bacterial Keratitis: Isolated Organisms and Antibiotic Resistance Patterns in San Francisco.

Authors:  Michelle Y Peng; Vicky Cevallos; Stephen D McLeod; Thomas M Lietman; Jennifer Rose-Nussbaumer
Journal:  Cornea       Date:  2018-01       Impact factor: 2.651

3.  Studies on molecular characterizations of the outer membrane proteins, lipids profile, and exopolysaccharides of antibiotic resistant strain Pseudomonas aeruginosa.

Authors:  Hany M Yehia; Wesam A Hassanein; Shimaa M Ibraheim
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

4.  High-throughput automated microfluidic sample preparation for accurate microbial genomics.

Authors:  Soohong Kim; Joachim De Jonghe; Anthony B Kulesa; David Feldman; Tommi Vatanen; Roby P Bhattacharyya; Brittany Berdy; James Gomez; Jill Nolan; Slava Epstein; Paul C Blainey
Journal:  Nat Commun       Date:  2017-01-27       Impact factor: 14.919

5.  Ten-year analysis of microbiological profile and antibiotic sensitivity for bacterial keratitis in Korea.

Authors:  Yongseok Mun; Mee Kum Kim; Joo Youn Oh
Journal:  PLoS One       Date:  2019-03-01       Impact factor: 3.240

6.  Antibiotic Resistance Characteristics of Pseudomonas aeruginosa Isolated from Keratitis in Australia and India.

Authors:  Mahjabeen Khan; Fiona Stapleton; Stephen Summers; Scott A Rice; Mark D P Willcox
Journal:  Antibiotics (Basel)       Date:  2020-09-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.